Literature DB >> 7577419

Role of platelets in progressive glomerular diseases.

C Zoja1, G Remuzzi.   

Abstract

There is increasing evidence that platelets are involved in the pathogenesis of glomerulonephritis. Intraglomerular platelets or their degradation products are observed in biopsies from patients with lupus nephritis, mesangioproliferative, membranous or IgA nephropathy. Moreover shortened platelet survival in patients with various glomerular diseases has also been described. In models of experimental glomerulonephritis, platelets may participate in glomerular injury, together with other mediators, by complex mechanisms. As extensively documented, platelets release within the glomerulus vasoactive, chemotactic and mitogenic substance that interact with a number of soluble mediators generated by renal resident or inflammatory cells and contribute to amplify glomerular injury. Thus platelet-activating factor and other platelet secretory products, polycationic macromolecules, platelet factor 4 and beta-thromboglobulin, alter glomerular permeability to proteins and enhance immune-mediated glomerular injury. Platelet-derived factors, like platelet-derived growth factor (PDGF) and transforming growth factor beta (TGF beta) mediate renal disease progression in experimental and human glomerulonephritis via their chemotactic activity for infiltrating leucocytes and their effect of promoting extracellular matrix synthesis by resident renal cells. In these settings increased renal expression of PDGF and TGF beta has correlated with clinical features. Specific PDGF and TGF beta inhibitors ameliorated experimental glomerular disease. A wide variety of therapies to inhibit platelet function have been employed over the years, however the results of clinical studies are controversial and do not allow conclusions to be drawn about the efficacy of anti-platelet agents in progressive renal disease. Identification of specific platelet inhibitors or interventions specific for platelet secretory products and their target cells will be crucial for understanding the exact role of platelets and their products in glomerular disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7577419     DOI: 10.1007/BF00866739

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  78 in total

Review 1.  Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin.

Authors:  S Moncada; J R Vane
Journal:  Pharmacol Rev       Date:  1978-09       Impact factor: 25.468

2.  The role of blood and platelets in atherosclerosis and the complications of atherosclerosis.

Authors:  J F Mustard; M A Packham
Journal:  Thromb Diath Haemorrh       Date:  1975-06-30

3.  Glomerular localization of platelet cationic proteins after immune complex-induced platelet activation.

Authors:  J l Barnes; G Camussi; C Tetta; M A Venkatachalam
Journal:  Lab Invest       Date:  1990-12       Impact factor: 5.662

4.  Expression of transforming growth factor-beta 1 and beta 2 in rat glomeruli.

Authors:  K MacKay; P Kondaiah; D Danielpour; H A Austin; P D Brown
Journal:  Kidney Int       Date:  1990-12       Impact factor: 10.612

5.  Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy.

Authors:  J V Donadio; C F Anderson; J C Mitchell; K E Holley; D M Ilstrup; V Fuster; J H Chesebro
Journal:  N Engl J Med       Date:  1984-05-31       Impact factor: 91.245

6.  Agents that increase cAMP accumulation block endothelial c-sis induction by thrombin and transforming growth factor-beta.

Authors:  T O Daniel; V C Gibbs; D F Milfay; L T Williams
Journal:  J Biol Chem       Date:  1987-09-05       Impact factor: 5.157

7.  Platelet-derived growth factor expression in mesangial proliferative glomerulonephritis.

Authors:  L Gesualdo; M Pinzani; J J Floriano; M O Hassan; N U Nagy; F P Schena; S N Emancipator; H E Abboud
Journal:  Lab Invest       Date:  1991-08       Impact factor: 5.662

8.  Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease.

Authors:  W A Border; N A Noble; T Yamamoto; J R Harper; Y u Yamaguchi; M D Pierschbacher; E Ruoslahti
Journal:  Nature       Date:  1992-11-26       Impact factor: 49.962

9.  Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin.

Authors:  G Ciabattoni; G A Cinotti; A Pierucci; B M Simonetti; M Manzi; F Pugliese; P Barsotti; G Pecci; F Taggi; C Patrono
Journal:  N Engl J Med       Date:  1984-02-02       Impact factor: 91.245

10.  Effect of platelet-activating factor and its specific receptor antagonist on glomerular permeability to proteins in isolated perfused rat kidney.

Authors:  N Perico; F Delaini; M Tagliaferri; M Abbate; M Cucchi; T Bertani; G Remuzzi
Journal:  Lab Invest       Date:  1988-02       Impact factor: 5.662

View more
  6 in total

1.  Platelet-derived growth factor and platelet profiles in childhood nephrotic syndrome.

Authors:  Anna M Wasilewska; Walentyna M Zoch-Zwierz; Barbara Tomaszewska; Anna Biernacka
Journal:  Pediatr Nephrol       Date:  2004-10-13       Impact factor: 3.714

2.  Platelet recruitment to the inflamed glomerulus occurs via an alphaIIbbeta3/GPVI-dependent pathway.

Authors:  Sapna Devi; Michael P Kuligowski; Rain Y Q Kwan; Erik Westein; Shaun P Jackson; A Richard Kitching; Michael J Hickey
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

Review 3.  The non-haemostatic role of platelets in systemic lupus erythematosus.

Authors:  Petrus Linge; Paul R Fortin; Christian Lood; Anders A Bengtsson; Eric Boilard
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

Review 4.  Platelets: active players in the pathogenesis of arthritis and SLE.

Authors:  Eric Boilard; Patrick Blanco; Peter A Nigrovic
Journal:  Nat Rev Rheumatol       Date:  2012-08-07       Impact factor: 20.543

Review 5.  Platelet abnormalities in nephrotic syndrome.

Authors:  Benedicte Eneman; Elena Levtchenko; Bert van den Heuvel; Chris Van Geet; Kathleen Freson
Journal:  Pediatr Nephrol       Date:  2015-08-13       Impact factor: 3.714

6.  Glycoprotein VI in securing vascular integrity in inflamed vessels.

Authors:  Yacine Boulaftali; Marie-Anne Mawhin; Martine Jandrot-Perrus; Benoît Ho-Tin-Noé
Journal:  Res Pract Thromb Haemost       Date:  2018-04-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.